Appointments to the management of RQM+

Ronnie Mahofski and Kevin Rowland Named Executive Vice Presidents and General Managers

PITTSBURGH- RQM+ , a leading global provider of medical technology services (contract research organization, CRO), today announced the appointments of Ronnie Mahofski and Kevin Rowland , both as executive vice presidents and general managers. Mr. Mahofski will lead the Consulting Services and Fern.ai business units, while Mr. Rowland will lead Jordi Labs, an RQM+ company .

“These strategic appointments reflect RQM+’s commitment to returning to its founding principles, those that made us industry pioneers. We are confident that Ronnie and Kevin’s leadership will enable us to continue our mission: to deliver innovative, safe and effective medical technologies to patients who need them,” said John Potthoff , President and CEO of RQM+.

In his new role, Mr. Mahofski will oversee the regulatory and quality consulting services and associated business development team, while leading technology enablement efforts with Fern.ai. Ronnie joined RQM+ in 2015, where he held key roles in business development and as head of mergers and acquisitions.

Kevin Rowland has played a key role at Jordi Labs for nearly 15 years, holding various positions including Head of the GCMS and LCMS groups, as well as Laboratory Director and Head of Research and Development. He specializes in analyzing high-resolution mass spectrometry data to identify off-target and unknown compounds. In his new role, Kevin continues to provide world-class service to Jordi Labs’ clients, while ensuring the safety of products for patients.

About RQM+

RQM+ is a leader in medical technology, providing consulting, clinical trial, laboratory and reimbursement services, as well as technology solutions to support the entire product lifecycle.

About Jordi Labs, an RQM+ company

Jordi Labs, an RQM+ company , provides the highest quality contract testing services to the world’s leading manufacturers of consumer products, polymers, pharmaceuticals and medical devices. Our team of analytical chemists, all PhDs, specialize in chemical identification. Extractables and leachables analysis is one of our core expertise.

About Fern.ai

Fern.ai, an RQM+ company, is an AI and machine learning platform for life sciences that enables customers to easily manage compliance requirements and efficiently adapt to changing regulatory environments. It is the only comprehensive platform designed to optimize the entire medical technology lifecycle, ensuring quality, speed to market, and compliance from concept to commercialization.

The text of the press release resulting from a translation should in no way be considered official. The only version of the press release that is authoritative is that of the press release in its original language. The translation must always be compared with the source text, which will constitute precedent.